A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells
- PMID: 3259468
A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells
Abstract
Lymphocytes from human peripheral blood incubated with interleukin-2 (IL2) develop lymphokine-activated killer (LAK) activity with the ability to kill a wide variety of tumor cells in a non-major histocompatibility complex-restricted manner. Adoptive immunotherapy with LAK cells and IL2 has been reported to lead to a regression of solid tumors in some patients with advanced malignancies. Aiming to improve the effectiveness of clinical adoptive immunotherapy, we developed a procedure for selective enrichment from human blood mononuclear cells (MNC) of IL2-activated antitumor effector cells. These cells, termed adherent LAK (A-LAK) cells because of their characteristic property of adherence to plastic, demonstrated both higher proliferative potential and greater antitumor cytotoxicity than unseparated MNC. Human A-LAK cells represented only 1 to 4% of IL2-activated MNC at 24 h but expanded from 130- to 1100-fold in 20 days. They comprised a population highly enriched in CD3-Leu19+ effector cells with antitumor activity against fresh human solid tumor cells and established cell lines. A-LAK cells retained antitumor activity for up to 14 days when cultured in the presence of IL2. They also mediated antibody-dependent cytotoxicity. Large-scale generation of A-LAK cells from the blood of patients with cancer proved feasible and should yield populations that are effective in vivo at lower doses than those required with unseparated LAK cells. This offers the potential for improving the antitumor effects, reducing the toxicity, and facilitating the administration of adoptive immunotherapy in humans. A Phase I/II clinical trial utilizing A-LAK cells and IL2 in patients with melanoma and renal cell carcinoma is now in progress.
Similar articles
-
In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.Cancer Res. 1988 Nov 1;48(21):6069-75. Cancer Res. 1988. PMID: 2971433
-
Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.Cancer Res. 1988 Aug 1;48(15):4409-16. Cancer Res. 1988. PMID: 3260537
-
Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.Cancer Res. 1989 Mar 15;49(6):1441-6. Cancer Res. 1989. PMID: 2784350
-
The biology of human natural killer cells.Ann Ist Super Sanita. 1990;26(3-4):335-48. Ann Ist Super Sanita. 1990. PMID: 2091502 Review.
-
[LAK cells and cancer].Gan To Kagaku Ryoho. 1986 Dec;13(12):3327-33. Gan To Kagaku Ryoho. 1986. PMID: 3539024 Review. Japanese.
Cited by
-
Unimpaired ability to generate adherent lymphokine-activated killer (A-LAK) cells in patients with primary or metastatic liver tumors.Cancer Immunol Immunother. 1989;30(5):312-6. doi: 10.1007/BF01744900. Cancer Immunol Immunother. 1989. PMID: 2624925 Free PMC article.
-
Kinetics of interleukin-2 induced changes in rigidity of human natural killer cells.Cell Biophys. 1992 Apr-Jun;20(2-3):161-76. doi: 10.1007/BF02823656. Cell Biophys. 1992. PMID: 1285298
-
Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.Clin Exp Immunol. 1995 Aug;101(2):362-8. doi: 10.1111/j.1365-2249.1995.tb08365.x. Clin Exp Immunol. 1995. PMID: 7648722 Free PMC article.
-
Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.Klin Wochenschr. 1990 Jan 4;68(1):1-11. doi: 10.1007/BF01648882. Klin Wochenschr. 1990. PMID: 2407894 Review.
-
Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer.J Transl Med. 2015 Aug 25;13:277. doi: 10.1186/s12967-015-0632-8. J Transl Med. 2015. PMID: 26303618 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources